ERBB2 and breast cancer: MIAT levels showed a trend to be higher in the luminal breast cancer subtype, and KCNQ1OT1 (luminal vs. HER2+, p = 2.41 × 10−2; luminal vs. TNBC, p = 0.05), LOC100270804 (luminal vs. HER2+, p = 2.79 × 10−2; luminal vs. TNBC, p = 5.16 × 10−3), and FLJ10038 (luminal vs. HER2+, p = 2.17 × 10−7; luminal vs. TNBC, p = 4.47 × 10−12) median levels were found to be significantly higher in the luminal subtype.